The Hematology Podcast Sanofi

Acute myeloid leukemia (AML) is a hematopoietic stem cell-derived myeloid malignancy characterized by manifold genetic aberrations and poor overall survival. Standard treatment for newly diagnosed fit AML patients is intensive chemotherapy. Relapse is, however, a challenge in more than 40% of AML patients. AML is also a disease with a large degree of individual heterogeneity, which creates challenges both for diagnostics and for developing targeted treatment options. 


Our guest is Björn Gjertsen, professor of hematology at the University of Bergen, Norway. Björn is also part of Centre for Cancer Biomarkers, CCBIO, and founding member and chair of the Nordic AML group and member of HOVON AML International Steering Group. He has extensive experience in treating AML, in clinical and translational research of AML, including very exciting newly published data on how single cell signalling profiling may help to detect responders and non-responders early in the treatment. 




MAT-BE-2400183 (ver. 1) Feb 2024

Smoldering multiple myeloma (SMM) is an intermediate condition that lies between Monoclonal gammopathy of undetermined significance (MGUS) and active multiple myeloma along the spectrum of clonal plasma cell proliferative disorders. Smoldering multiple myeloma may take years to become active multiple myeloma. In some cases, people who have this condition never develop active multiple myeloma. 
In this episode we have the pleasure of having the Norwegian haematologist Fredrik Schjesvold with us. Fredrik is the founder and leader of Oslo Myeloma Center at Oslo University Hospital. Fredrik is an international expert on Multiple Myeloma in charge of one of Europe’s largest centres for clinical research in this disease. He is also chairman of the Nordic Myeloma Study Group and leads the Norwegian Myeloma Group. Besides he is member of the International Myeloma Working Group, and board member of the European Myeloma network (EMN).

 MAT-BE-2400119  (ver. 1)  02.2024

Thalassemia is a hereditary blood disorder, in which the synthesis of hemoglobin chains is impaired.  Consequently, people with thalassemia minor may have slight to severe anemia which usually does not cause any problems. Thalassemia major in contrast is a severe disorder with need of transfusion and complications with iron overload. In this episode we will mainly discuss thalassemia minor and intermedia. 
Our guest today Professor Bart Biemond is a hematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. Today, Bart will tell us more about thalassemia, its clinical implications and developments in research which implicate patients today and in the future.

MAT-BE-2400104 (v.1.0)) February 2024

Today we will discuss a rare, inherited metabolic disorder known as ASMD, acid sphingomyelinase deficiency (or historically known as Niemann-Pick types A, A/B, and B). This genetic condition is very rare. It can be diagnosed, after suspicion, by different screening test. But symptoms may vary greatly, and has overlap with several other disorders, and the road to an accurate diagnosis can therefore be challenging. 
In today’s episode we have the pleasure of welcoming Professor David Cassiman in the studio. He is a specialist in hepatology with profound knowledge of metabolic diseases. He currently works at the University Hospital of Leuven (Belgium) where he is the head of the Center for Heridatary Metabolic Diseases. He has spent several years of research, diagnosing, and treating patients with different rare metabolic disorders.

MAT-BE-2301084 (ver.1) 3 Nov 2023

Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD).

In this episode we have the pleasure of having the Belgian Assistant professor Dr Amaryllis Van Craenenbroeck with us in the studio.  She is Assistant professor at UZ Leuven and specialises in kidney transplantation and kidney diseases.



MAT-BE-2301080 (ver.1) Oct 2023

Sickle cell disease (SCD) is a hereditary blood disorder, where red blood cells have the shape of a C or sickle - hence the name. Sickle cells have a shorter lifespan than normal red blood cells, which causes anemia. Additionally, sickle cells may block blood vessels, especially during infections, dehydration, stress or fatigue, causing complications for the patients.
 
Our guest today Professor Bart Biemond is a haematologist at the Amsterdam UMC in The Netherlands. Bart is head of the Hemoglobinopathy Expert Center and an active member of the medical advisory boards of the national patient associations. His efforts in research have led among others to greater understanding of biomarkers in SCD and complications associated with this disease. In this episode of our Haematology Podcast, Bart will tell us more about SCD, its clinical implications and developments in research which implicate patients today and in the future. 



MAT-BE-2300066 (ver.1) July 2023